Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

which has two cell therapies codenamed VX-880 and VX-264 in early-stage clinical trials. VX-880 is not encapsulated, so needs immunosuppression and could face similar issues to Lantidra ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX-880) ...